Navin Fluorine - Life Sciences, An Ever Growing Opportunity: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
From the first fluoro-pharmaceutical drug in CY54 – Florinef, fluoro compounds have found an ever increasing acceptance in new pharmaceutical drugs. Around 40% of new registered drugs are fluoro-pharmaceutical drugs. Even the largest selling drug of all times – Lipitor – is a fluoro-pharmaceutical drug.
Navin Fluorine International Ltd., with nearly five decades of experience in fluorination, is expected to benefit from the growing usage of fluoro-pharmaceuticals.
Navin Fluorine is building an Rs 2 billion multi-purpose plant by H1 FY23. The multi-purpose plant would exploit opportunities in life sciences and crop protection, with an expected asset turnover of ~1.4 times (i.e. ~25% of total revenue in FY21).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.